The Cancer Prevention and Control (CPC) Program is focused on scientific discovery across the cancer continuum?from primary prevention to survivorship?that translates into clinical, community, and policy strategies to improve cancer outcomes. The CPC Program has 25 members in 13 departments led by a new leadership team appointed in 2015. Kristie Foley, Ph.D., is the Program Leader and Associate Director for Population Sciences, and Kathryn Weaver, Ph.D., serves as Program Co-Leader and Assistant Director of the Office of Cancer Health Equity. This team guides the scientific direction of the Program, education and training of post-doctoral fellows and early-stage faculty, and integration of CPC with other Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) Programs. Program members conduct research that is relevant to the WFBCCC catchment area: 4.1 million residents in 58 counties, which are predominantly Appalachian (n=46), non-metropolitan/rural (n=37) regions. The 23,100 annual new cancer cases and 9,000 cancer deaths in the WFBCCC catchment area are 3% and 5% higher than nationwide rates for all cancers combined. Addressing cancer disparities is a priority of the CPC Program?s research and a cross-cutting theme throughout its work. The CPC Program conducts rigorous, hypothesis-driven, and translatable research that is responsive to two Specific Aims to 1) Improve modifiable risk factors that will reduce cancer incidence, morbidity, and mortality, with a strategic focus on tobacco control and obesity; and 2) Enhance survivorship outcomes, with a focus on quality of life, while incorporating patient-reported outcomes into survivorship care and addressing the symptoms and long-term effects of cancer treatment.
These Aims guide CPC programmatic strategies, which include hypothesis-driven research tied to catchment area needs; integration with key institutional resources such as the Wake Forest National Cancer Institute Community Oncology Research Program; collaboration with other WFBCCC Programs, regional Comprehensive Cancer Centers, and community partners; education and training of scientists committed to population health research; and organizational strategies that promote the scientific vision and Aims of the CPC Program. Program members have $5.2M in peer-reviewed, cancer-related direct funding of which 58.7% is from the NCI (excluding $.9M in peer-rev training grants). In this funding period, CPC members produced 370 publications; 44.3% were intra-programmatic, 13.2% were inter-programmatic, and 79.5% were inter-institutional, with 11.1% of publications in journals with an impact factor >10. The CPC Program is in a dynamic new phase: 3 new faculty members were recruited in the past year; and 4 to 5 more new faculty recruitments will occur in the next 5 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-45
Application #
9848543
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Westcott, Marlena M; Clemens, Elene A; Holbrook, Beth C et al. (2018) The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine 36:1174-1182
Ruiz, Jimmy; Miller, Antonius A; Tooze, Janet A et al. (2018) Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol :
Levine, Edward A; Votanopoulos, Konstantinos I; Shen, Perry et al. (2018) A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. J Am Coll Surg 226:434-443
Addington, Elizabeth L; Sohl, Stephanie J; Tooze, Janet A et al. (2018) Convenient and Live Movement (CALM) for women undergoing breast cancer treatment: Challenges and recommendations for internet-based yoga research. Complement Ther Med 37:77-79
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681
Suo, Xubin; Eldridge, Brittany N; Zhang, Han et al. (2018) P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces 10:33464-33473
Widner, D Brooke; Park, Sun H; Eber, Matthew R et al. (2018) Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep 16:596-602
Liu, Liang; Ruiz, Jimmy; O'Neill, Stacey S et al. (2018) Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 17:81
Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514

Showing the most recent 10 out of 548 publications